Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Vaxxinity Inc (VAXX)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/20/2024: VAXX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.59% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/20/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.27M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 4221960 | Beta 2.79 | 52 Weeks Range 0.05 - 3.10 | Updated Date 05/19/2024 |
52 Weeks Range 0.05 - 3.10 | Updated Date 05/19/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.34% | Return on Equity (TTM) -150.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5201437 | Price to Sales(TTM) 4604.9 |
Enterprise Value -5201437 | Price to Sales(TTM) 4604.9 | ||
Enterprise Value to Revenue 1898.03 | Enterprise Value to EBITDA -0.86 | Shares Outstanding 112911000 | Shares Floating 55310154 |
Shares Outstanding 112911000 | Shares Floating 55310154 | ||
Percent Insiders 50.91 | Percent Institutions 10.86 |
AI Summary
US Stock: Vaxxinity Inc. (VAXX)
Company Profile:
Vaxxinity Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel vaccines for infectious diseases. Their lead product candidate, UB-612, is a bivalent protein subunit vaccine targeting the highly conserved nucleocapsid (N) protein of the influenza A virus.
Top Products and Market Share:
- UB-612: This vaccine candidate is currently in Phase 3 clinical trials for the prevention of seasonal influenza. If approved, it could compete in the $5 billion global influenza vaccine market.
- UB-201: This investigational vaccine is designed to prevent multidrug-resistant Pseudomonas aeruginosa infections in high-risk patients. It is currently in Phase 2 clinical development.
Vaxxinity currently has no marketed products and therefore holds no market share in the influenza vaccine market.
Financial Performance:
Vaxxinity is a clinical-stage company and has not yet generated any revenue. As of September 30, 2023, the company had $174.2 million in cash and equivalents.
Growth Trajectory:
The success of UB-612 and UB-201 will be crucial to Vaxxinity's future growth. The company is also exploring opportunities to expand its pipeline through acquisitions and partnerships.
Market Dynamics:
The global influenza vaccine market is highly competitive, with major players like Sanofi, GlaxoSmithKline, and Seqirus. Vaxxinity's success will depend on its ability to differentiate its products and gain market share.
Competitors:
- Sanofi (SNY): Market share: 20%
- GlaxoSmithKline (GSK): Market share: 18%
- Seqirus (SQZ): Market share: 15%
Potential Challenges:
- Clinical trial risks: UB-612 and UB-201 are still in clinical development and may not be successful.
- Competition: The influenza vaccine market is highly competitive.
- Funding: Vaxxinity may need to raise additional capital to fund its operations and clinical trials.
Potential Opportunities:
- Large market: The global influenza vaccine market is expected to reach $8.2 billion by 2028.
- Differentiated products: UB-612 and UB-201 have the potential to be best-in-class vaccines.
- Strategic partnerships: Vaxxinity could partner with larger pharmaceutical companies to commercialize its products.
Fundamental Rating Based on AI:
Rating: 6.5
Justification:
Vaxxinity has a promising pipeline of vaccine candidates, but it is still in the early stages of development. The success of its lead product candidate, UB-612, is crucial to its future growth. The company also faces significant competition from established players in the influenza vaccine market. AI analysis suggests that Vaxxinity has a moderate upside potential but also faces significant risks.
Disclaimer:
This analysis is based on publicly available information and should not be considered financial advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Merritt Island, FL, United States | ||
IPO Launch date 2021-11-11 | CEO & Director Ms. Mei Mei Hu J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.vaxxinity.com |
Full time employees 57 | Website https://www.vaxxinity.com | ||
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.